Parameter OR 95% Wald Confidence Standard P value Limits Error Treatment regimen 0.46 0.22 0.98 0.19 0.04 (telaprevir vs boceprevir) 1.02 0.98 1.06 0.02 0.38 Age Gender (male vs 2.30 1.05 5.04 0.20 0.04 female) Treatment status 0.47 0.22 0.99 0.19 0.05 (treatment naïve vs experienced) HIV co-infection (n=10) 1.62 0.42 6.27 0.35 0.49 (presence vs absence) Liver disease 3.13 1.19 8.22 0.25 0.02 (No cirrhosis vs cirrhosis) Depression (n=40) 0.67 0.30 1.46 0.20 0.31 (presence vs absence) Diabetes (n=8) 1.04 0.20 5.33 0.42 0.97 (presence vs absence) Table S2 Repartition of AEs according to the association with treatment (N) (N) Total “likely” (N) “can’t tell” “unlikely” Skin problem 88 0 0 88 (49%) Other* 25 24 13 62 (35%) Anaemia 22 0 0 22 (12%) Neutropenia 6 0 0 6 (3%) Total 141 24 13 178 Table S3 List of 25 AEs assessed related classified as “Other” and as “likely” to treatment
Parameter OR 95% Wald Confidence Limits Standard Error P value Treatment regimen (telaprevir vs boceprevir) 0.46 0.22 0.98 0.19 0.04 Age 1.02 0.98 1.06 0.02 0.38 Gender (male vs female) 2.30 1.05 5.04 0.20 0.04 Treatment status (treatment naïve vs experienced) 0.47 0.22 0.99 0.19 0.05 HIV co-infection (n=10) (presence vs absence) 1.62 0.42 6.27 0.35 0.49 Liver disease (No cirrhosis vs cirrhosis) 3.13 1.19 8.22 0.25 0.02 Depression (n=40) (presence vs absence) 0.67 0.30 1.46 0.20 0.31 Diabetes (n=8) (presence vs absence) 1.04 0.20 5.33 0.42 0.97 Table S2 Repartition of AEs according to the association with treatment “likely” (N) “can’t tell” (N) “unlikely” (N) Total Skin problem 88 0 0 88 (49%) Other* 25 24 13 62 (35%) Anaemia 22 0 0 22 (12%) Neutropenia 6 0 0 6 (3%) Total 141 24 13 178 Table S3 List of 25 AEs classified as “Other” and assessed as “likely” related to treatment
41124_2016_2_MOESM1_ESM.docx